SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CNX-774

Item No. 21475

CAS Registry No.:	1202759-32-7
Formal Name:	4-[4-[[5-fluoro-4-[[3-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
MF:	$C_{26}H_{22}FN_7O_3$
FW:	499.5
Purity:	≥98%
UV/Vis.:	λ_{max}: 272 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CNX-774 is supplied as a crystalline solid. A stock solution may be made by dissolving the CNX-774 in the solvent of choice. CNX-774 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CNX-774 in these solvents is approximately 25 and 30 mg/ml, respectively.

CNX-774 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CNX-774 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CNX-774 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CNX-774 is a potent, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK), an important kinase in the B cell antigen receptor pathway, with IC_{50} values of <1 nM in biochemical assays and 1-10 nM in cellular assays.[1] It inhibits proliferation in HMC-1.1 and HMC-1.2 cells (IC_{50} = 2.82 and 0.38 µM) but has no effect on cell cycle progression.[2]

References

1. Akinleye, A., Chen, Y., Mukhi, N., *et al.* Ibrutinib and novel BTK inhibitors in clinical development. *J. Hematol. Oncol.* **6(59)** (2013).
2. Smiljkovic, D., Blatt, K., Stefanzl, G., *et al.* BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. *Allergy* 1-11 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM